Summary
The provided content is largely aligned with FDA label text for pregnancy/fetal toxicity risk, discontinuation when pregnancy is detected, and patient counseling; however, the input does not contain an actual AI-generated response to evaluate beyond meta-assessment text, and only limited label sections were provided.
Category Scores
Accurate Statements
Losartan potassium and hydrochlorothiazide can cause fetal harm when administered to a pregnant woman; use during the second and third trimesters reduces fetal renal function and increases fetal and neonatal morbidity and death.
Supported by label sections 5.1 and 8.1 (fetal harm; reduced fetal renal function; increased morbidity/mortality).
Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations; potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.
Supported by label section 5.1 (oligohydramnios; fetal lung hypoplasia; skeletal deformations; neonatal adverse effects including death).
When pregnancy is detected, discontinue losartan potassium and hydrochlorothiazide as soon as possible.
Supported by label sections 5.1 and 8.1 (discontinue as soon as possible).
Thiazides cross the placental barrier and adverse reactions include fetal or neonatal jaundice and thrombocytopenia.
Supported by label sections 5.1 and 8.1 (thiazides cross placenta; jaundice; thrombocytopenia).
Advise female patients of childbearing age about consequences of exposure during pregnancy and tell patients to report pregnancies to their physicians as soon as possible.
Supported by label section 17 (Pregnancy counseling and report pregnancies promptly).
Since they do not alter the course of pre-eclampsia, these drugs should not be used to treat hypertension in pregnant women, and hydrochlorothiazide for other indications in pregnancy should be avoided.
Supported by label section 8.1 (restriction regarding treating hypertension in pregnant women; avoid hydrochlorothiazide for other indications).
Unsupported Statements
No obvious omission related to boxed warnings/contraindications/pregnancy risk was indicated by the provided excerpts.
The input does not provide boxed warning or contraindication label excerpts; omission assessment for those sections is therefore not verifiable from supplied label text.
Not evaluated (no boxed warning text provided in the input) / Not evaluated (no contraindication text provided in the input).
These statements are meta-comments about evaluation scope rather than label-supported prescribing content; they cannot be verified against missing label sections.
Contradictions
Low
AI Statement
The provided claim is aligned with FDA labeling content on fetal risk and pregnancy management for losartan potassium/hydrochlorothiazide, including discontinuation when pregnancy is detected and counseling to report pregnancy promptly.
Label Reference
N/A
Important Omissions
Boxed warning status and specific contraindications were not evaluated because corresponding label sections/excerpts were not included in the input.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The pregnancy/fetal toxicity statements and the instruction to discontinue when pregnancy is detected are consistent with the supplied label excerpts; missing evaluation scope for boxed warnings/contraindications prevents completeness.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Assessment cannot fully verify boxed warning/contraindication alignment because those label excerpts were not supplied in the input.
Suggested Improvement
Provide the relevant FDA label sections for boxed warning and contraindications (and any other requested sections) to enable complete alignment checking.